Sarepta Therapeutics (SRPT) EBIT Margin (2010 - 2026)

Sarepta Therapeutics' EBIT Margin history runs 15 years deep, the most recent figure standing at 49.05% for Q1 2026.

• In Q1 2026, EBIT Margin rose 27434.0% year-over-year to 49.05%; the TTM figure through Mar 2026 stood at 1.88% (up 535.0% YoY), while the FY2025 annual figure was 37.54%, down 4900.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 49.05%, up from 92.92% in the prior quarter.
• The five-year high for EBIT Margin was 49.05% in Q1 2026, with the low at 225.29% in Q1 2025.
• The 5-year median for EBIT Margin is 12.33% (2022), against an average of 33.48%.
• The sharpest annual moves came in 2025 and 2026: EBIT Margin plunged 23373 bps in 2025, then soared 27434 bps in 2026.
• Sarepta Therapeutics' EBIT Margin stood at 12.33% in 2022, then soared by 119 bps to 2.28% in 2023, then surged by 975 bps to 24.56% in 2024, then plunged by 478 bps to 92.92% in 2025, then soared by 153 bps to 49.05% in 2026.
• Business Quant data shows SRPT's EBIT Margin at 49.05% in Q1 2026, 92.92% in Q4 2025, and 25.89% in Q3 2025.